



Asuragen Appoints Lyle Arnold, Ph.D., to Board of Directors

Austin, Texas – March 30, 2010. Asuragen, Inc., a leader in molecular diagnostic development, announced today the appointment of Lyle Arnold, Ph.D., to its board of directors.

Dr. Arnold is a veteran biotechnology entrepreneur and a leading developer of novel technologies for the molecular diagnostic industry. Previously he was VP, Research at Gen-Probe from September 2003 to October 2009. Dr. Arnold also was associated with Gen-Probe from 1985 to 1989 as head of technology research. He has held senior scientific and management positions at Molecular Biosystems (co-founder), Genta, Synteni, Incyte Genomics, and Oasis Biosciences (co-founder), where he was President and Chief Scientific Officer from October 2001 to September 2003. Dr. Arnold was a faculty member in the UCSD School of Medicine and a member of the UCSD Cancer Center. Dr. Arnold is an inventor on 36 issued U.S. patents and more than 140 issued and pending patents worldwide. He has authored more than 50 scientific publications. Dr. Arnold received a B.S. in Chemistry from the University of California at Los Angeles and a Ph.D. in Chemistry/Biochemistry from the University of California at San Diego. He currently works as an independent consultant and recently founded Aegea Biotechnologies.

“We are pleased to welcome Lyle to the Asuragen board as we continue to assess and implement next generation molecular technologies,” said CEO and Chairman of the Board, Matt Winkler. “Lyle has played a pioneering role in the field of molecular diagnostics and his extensive development experience is a great addition.”

“Asuragen’s breadth of capability from its early discovery work in microRNAs, to biomarker discovery, assay development and the commercialization of molecular diagnostics makes it well positioned to capitalize on the emerging field of companion diagnostics,” commented Lyle Arnold. “I’m pleased to join the board and look forward to providing strategic guidance as Asuragen commercializes novel RNA-based molecular tests for clinically significant biomarkers in oncology.”

About Asuragen

Asuragen is a fully integrated molecular diagnostic company and pharmaceutical services provider. The Company’s diagnostic product portfolio consists of the first-ever validated microRNA diagnostic assay for pancreatic cancer, quantitative RNA tests for leukemia gene translocations, and the Signature[®] Oncology Testing products. Asuragen is empowered with a high level of scientific expertise and assay development capabilities, CLIA and GLP testing services, and an established cGMP manufacturing facility, which allow it to span the spectrum of discovery, testing, production and commercialization. For more information, visit www.asuragen.com.

###

Contact:

Rollie Carlson
President
Asuragen, Inc.
512.681.5200
rcarlson@asuragen.com

Asuragen, Inc.
2150 Woodward St., Suite 100
Austin, TX 78744
PH: 512.681.5200
T: 877.777.1874
F: 512.681.5201
www.asuragen.com